Merck Frosst Canada, Inc.

Aeromics, Inc.

Merck Frosst Canada & Co.

St. Jude Children's Research Hospital

Debiopharm International, S.a.

Coa Therapeutics, Inc.

Merck + Co., Inc.

Amgen Inc.

Cantero Therapeutics, Inc.

Zamboni Chem Solutions Inc.

Robert J Zamboni

Robert N Young

John Colucci

Paul Robert Mcguirk

Helmi Zaghdane

Jacques-Yves Gauthier

Erich L Grimm

Christopher I Bayly

Marc F Pelletier

George William Farr

Yongxin Han

Stephan D Parent

Michel Therien

Daniel Guay

Serge Leger

Petpiboon Prasit

Michel L Belley

Melanie Janelle Bevill

Andre Giroux

Anthony Marfat

John Joseph Partridge

Yves Leblanc

Haydn W Williams

Richard W Friesen

Richard Frenette

Richard Edward Lee

Renee Aspiotis

Yves Gareau

Daniel J McKay

T Jagadeeswar Reddy

Charles O Rock

Chitra Subramanian

Sylvie Desmarais

Suzanne Jackowski

Mi Kyung Yun

Barry Hafkin

Rajendra P Tangallapally

Anne V Edwards

Zhaoyin Wang

Jacques Yves Gauthier

Thomas R Verhoeven

Dustin L McMinn

Cameron Black

Patrick Roy

Claude Dufresne

Kathleen M Metters

Brian Gregory Lucas

Masatoshi Kakushima

Christian Beaulieu

Jacob A Kaizerman

Hans Maag

Dan McKay

Jiuyu Liu

Lalit Kumar Sharma

Marc LaBelle

Sebastien Francoeur

Elham Akbariromani

Johanne Renaud

Miguel Xavier Fernandes

Marc-Andre Beaulieu

Pallavi Thakur

Ryan Henning

Xian Alan Ji

Tyler Smith

Bradley Heller

Thumkunta Jagadeeswar Reddy

Sylvain Rocheleau

Marc Andre Beaulieu

Shawn Black

Richard E Lee

Jacob Kaizerman

Dustin L Mcminn

Provided are novel prodrug salts of selective aquaporin inhibitors, their use as pharmaceuticals, and pharmaceutical compositions comprising them, and novel processes for their synthesis and novel intermediates for use in their synthesis. Also provided is use of a compound for the prophylaxis, treatment, and control of aquaporin-mediated conditions. Aquaporin inhibitors, e.g., inhibitors of AQP4 and/or AQP2, may be of utility in the treatment or control of diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord), hyponatremia, and excess fluid retention, as well as diseases such as epilepsy, retinal ischemia and other diseases of the eye, myocardial ischemia, myocardial ischemia/reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines.

Prodrug salts

Provided are crystals of 2-{[3,5-bis(trifluoromethyl)phenyl]carbamoyl}-4-chlorophenyl dihydrogen phosphate, compositions comprising the same, and methods of making and using such crystals.

Crystals

The present disclosure relates to chemical compounds that modulate pantothenate kinase (PanK) activity for the treatment of metabolic disorders (such as diabetes mellitus type II), neurologic disorders (such as pantothenate kinase-associated neurodegeneration), pharmaceutical compositions containing such compounds, and their use in treatment. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Small molecule modulators of pantothenate kinases

The present disclosure relates to methods of treating a coenzyme A reduction, elevation, sequestration, toxicity, or redistribution (CASTOR) disease such as, for example, defects in fatty acid oxidation enzymes, methylmalonic acidemia, glutaric acidemia, propionic academia, and HMG-CoA lyase, via small molecule modulators of CoA levels. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Methods of treating disorders associated with castor

The present invention provides triazole carboxylic acids and related compounds, as well as pharmaceutically acceptable salts thereof, which are useful as glycolate oxidase inhibitors. Pharmaceutical compositions and methods for treating primary hyperoxaluria, type I (PH) and kidney stones are also described.

Triazole glycolate oxidase inhibitors

The present disclosure provides, inter alia, RAF-Degrading Conjugate Compounds that are useful in the treatment of cancer and other RAF related diseases. Also provided are, pharmaceutical compositions, methods of treatment, and kits comprising a RAF-Degrading Conjugate Compound.

RAF-degrading conjugate compounds

In part, the present disclosure is directed to prodrug derivatives of (E)-N-methyl-N-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide compounds with significant solubility and bioavailability profiles.

Prodrug derivatives of (E)-N-methyl-N-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide

Prodrug derivatives of (E)-N-methyl-N-((3-M ethylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamide

The present invention relates generally to compounds represented in Formula I, pharmaceutical compositions comprising them and methods of treating of diseases or disorders such as cancer. 

Pyridopyridazine compounds, compositions and methods of use

The present invention provides substituted tetrahydrocarbazole and cyclopentanoindole derivatives as antagonists of DP receptor, and as such are useful for the treatment of prostaglandin D2 mediated diseases such as rhinitis, asthma and nasal congestion.

Substituted tetrahydrocarbazole and cyclopentanoindole derivatives

Growing community of inventors

Longueuil, Canada

Robert J Zamboni